Empagliflozin reduces Ca/calmodulin‐dependent kinase II activity in isolated ventricular cardiomyocytes

AIMS: The EMPA‐REG OUTCOME study showed reduced mortality and hospitalization due to heart failure (HF) in diabetic patients treated with empagliflozin. Overexpression and Ca(2+)‐dependent activation of Ca(2+)/calmodulin‐dependent kinase II (CaMKII) are hallmarks of HF, leading to contractile dysfun...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:ESC Heart Fail
Hlavní autoři: Mustroph, Julian, Wagemann, Olivia, Lücht, Charlotte M., Trum, Maximilian, Hammer, Karin P., Sag, Can Martin, Lebek, Simon, Tarnowski, Daniel, Reinders, Jörg, Perbellini, Filippo, Terracciano, Cesare, Schmid, Christof, Schopka, Simon, Hilker, Michael, Zausig, York, Pabel, Steffen, Sossalla, Samuel T., Schweda, Frank, Maier, Lars S., Wagner, Stefan
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2018
Témata:
Short Communication
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6073019/
https://ncbi.nlm.nih.gov/pubmed/30117720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12336
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky